LBPH Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Longboard Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.80 |
| 52 Week High | US$59.95 |
| 52 Week Low | US$3.60 |
| Beta | 1.09 |
| 11 Month Change | 0.34% |
| 3 Month Change | 69.89% |
| 1 Year Change | 1,402.51% |
| 33 Year Change | 952.82% |
| 5 Year Change | n/a |
| Change since IPO | 259.16% |
Recent News & Updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28Recent updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth
Jul 12
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10Shareholder Returns
| LBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.08% | 1.6% | 2.2% |
| 1Y | 1,402.5% | 9.9% | 31.6% |
Return vs Industry: LBPH exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: LBPH exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| LBPH volatility | |
|---|---|
| LBPH Average Weekly Movement | 17.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LBPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LBPH's weekly volatility has decreased from 46% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 50 | Kevin Lind | www.longboardpharma.com |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases.
Longboard Pharmaceuticals, Inc. Fundamentals Summary
| LBPH fundamental statistics | |
|---|---|
| Market cap | US$2.33b |
| Earnings (TTM) | -US$76.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-30.6x
P/E RatioIs LBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.34m |
| Earnings | -US$76.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LBPH perform over the long term?
See historical performance and comparison